Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039833 | 1.00 | MEN1 (0.61) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL17822384 | 0.96 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL2737888 | 0.96 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL2737886 | 0.96 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL28339053 | 0.92 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL2737896 | 0.83 | MEN1 (0.48) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL2737899 | 0.83 | MEN1 (0.51) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL10031609 | 0.82 | HSD17B10 (0.57) | MEN1KMT2AALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL13871981 | 0.82 | HSD17B10 (0.57) | MEN1KMT2AALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL903389 | 0.82 | HSD17B10 (0.57) | MEN1KMT2AALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014094357-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | MEN1 619/4885KMT2A 1760/4885ALDH1A1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.